In the cancer context, PPAR-γ can negatively regulate the cell cycle, proliferation, and mobility of bladder cancer cells, and PPAR-γ agonists can reduce cell viability of GBM in different cell lines. This evidence concerns the gene PPARG and urinary bladder carcinoma.